Public Comments for: SB274 - Prescription Drug Affordability Board; established, drug cost affordability review, report.
On behalf of the nearly 850 people living with cystic fibrosis in Virginia, the Cystic Fibrosis Foundation writes to provide comments on SB 274. Please find our official comment letter attached. Thank you!
On behalf of the Virginia Association of Hematologists and Oncologists (VAHO) and the Association of Clinical Oncology (ASCO), I am submitting comments on S 274, attached. Thank you!
The National Minority Quality Forum (NMQF), a 501(c)(3) not-for-profit research and advocacy organization based in Washington, DC, is submitting the attached written testimony to share our concerns that a Virginia Prescription Drug Affordability Board (PDAB) may only serve to impede the progress toward achieving health care equity for all Virginians.
Honorable Members of the Virginia Legislature, The Alliance for Health Innovation (Alliance) is a group of diverse cross-sector stakeholders that together represent patients, providers, caregivers, academia, biopharmaceutical innovators, and business communities. Led by the Global Coalition on Aging (GCOA), the Alliance is committed to establishing the importance of innovation in achieving healthy aging and advocates for state policy solutions that support a thriving innovation sector that enables Virginians and other communities to live longer – and healthier – lives. We write to share our deep concerns about the potentially devastating impact of the newly proposed Prescription Drug Affordability Board (PDAB) on patients living in Virginia. Please see the attached letter for our concerns.
The Biotechnology Innovation Organization (BIO) respectfully opposes SB 274, which would create a Prescription Drug Affordability Board tasked with reviewing prescription drug costs and setting upper payment limits for specified prescription drugs. Government price controls like those proposed by this bill are an especially drastic action with unpredictable consequences. While the intent of this bill is to lower drug prices, we fear SB 274 will fail to bring down costs for consumers or institutions and instead disincentivize development of new therapeutic breakthroughs.